Iclusig® (Ponatinib)

Iclusig® (Ponatinib)

ICLUSIG® (ponatinib) is a kinase inhibitor indicated for the treatment of adult patients with: chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors, accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated, T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL. Learn more below.